Maryland Stem Cell Research Fund's Seraxis publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy
SERAXIS Inc., a rapidly growing regenerative medicine company today announced the publication of important trial considerations for SR-01, its pluripotent stem cell-derived islet therapy for insulin-dependent diabetes.
LEARN MORE